A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Another natural method that may help you find relief from environmental factors behind your post-nasal drip is by inhaling ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.